ViewRay logo
ViewRay VRAY
report update icon

Quarterly report 2023-Q1
added 05-23-2026

ViewRay Financial Statements 2022-2011 | VRAY

Annual Financial Statements ViewRay

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

477 M 716 M 657 M 318 M 583 M 522 M 209 M 85.4 M - - - -

Shares

181 M 165 M 148 M 102 M 81.1 M 58.5 M 40.1 M 17.4 M 892 K 815 K - -

Historical Prices

2.64 4.35 4.44 3.12 7.19 8.93 5.21 4.9 - - - -

Net Income

-107 M -110 M -108 M -120 M -76.4 M -72.2 M -50.6 M -45 M -33.8 M -27.2 M - -

Revenue

102 M 70.1 M 57 M 87.8 M 81 M 34 M 22.2 M 10.4 M 6.4 M 3.16 M - -

Cost of Revenue

92.2 M 69.8 M 61.1 M 93.3 M 74.4 M 27.7 M 25.9 M 14.5 M 9.15 M 8.19 M - -

Gross Profit

10 M 335 K -4.06 M -5.48 M 6.6 M 6.33 M -3.63 M -4.15 M -2.75 M -5.03 M - -

Operating Income

-107 M -104 M -106 M -121 M -75.1 M -48.2 M -44.2 M -41.4 M -31.6 M -27.1 M - -

Interest Expense

5.06 M 4.24 M 3.31 M 4.33 M 7.7 M 7.25 M 5.95 M 3.45 M 2.24 M 97 K - -

EBITDA

-102 M -97.6 M -99.6 M -116 M -71.7 M -46 M -42.6 M -40.3 M -30.7 M -26 M - -

Operating Expenses

117 M 104 M 102 M 115 M 81.7 M 54.5 M 40.5 M 37.3 M 28.8 M 22.1 M - -

General and Administrative Expenses

52.4 M 56.1 M 61.7 M 65.7 M 50.1 M 31.4 M 23.5 M 21.7 M 14.7 M 9.51 M - -

All numbers in USD currency

Quarterly Income Statement ViewRay

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

182 M 182 M 181 M 181 M 180 M 179 M 164 M 162 M 160 M 149 M 148 M 148 M 147 M 147 M 99 M 97.6 M 96.7 M 96.3 M 84.9 M 74.5 M 68.9 M 67.7 M 59.1 M 57.2 M 51.8 M 43.6 M 40.2 M 38.2 M 38.2 M 38.2 M 29.2 M 4.34 M 4.34 M 907 K 4.34 M 3.5 M 4.34 M 3.5 M 3.5 M 3.5 M - - - - - - - - -

Net Income

-28.9 M - -26.1 M -27.6 M -25.8 M - -25.3 M -31 M -26.7 M - -28.1 M -26.2 M -27.5 M - -20.8 M -30.8 M -33.4 M - -32.9 M -22 M -4.81 M - -11.2 M -8.35 M -28 M - -14.1 M -12.1 M -13.4 M - -10.3 M -1.61 K -4.11 K - -16.8 K -1.82 K -4.16 K 471 - - - - - - - - - - -

Revenue

22.5 M - 26.5 M 22.1 M 18.9 M - 19.2 M 15 M 15.5 M - 10.1 M 14.2 M 14.2 M - 20.9 M 30.2 M 20.3 M - 17.7 M 16.4 M 26.2 M - 12.2 M 698 K 1.23 M - 357 K 299 K 5.46 M - 5.32 M 182 K 280 K - 2.59 M - - - - - - - - - - - - - -

Cost of Revenue

24 M - 22 M 21.1 M 18.8 M - 17.3 M 16.7 M 15.2 M - 11.2 M 15.3 M 16.4 M - 20.3 M 26.9 M 25.6 M - 17.3 M 16.4 M 20.6 M - 10.2 M 826 K 1.04 M - 1.18 M 863 K 6.53 M - 6.09 M 833 K 777 K - 2.91 M - - - - - - - - - - - - - -

Gross Profit

-1.43 M - 4.45 M 1.09 M 94 K - 1.89 M -1.67 M 322 K - -1.06 M -1.04 M -2.11 M - 574 K 3.25 M -5.36 M - 364 K 69 K 5.57 M - 1.98 M -128 K 185 K - -826 K -564 K -1.07 M - -775 K -651 K -497 K - -317 K - - - - - - - - - - - - - -

Operating Income

-29.6 M - -23.9 M -29.8 M -27.5 M - -23.3 M -26.5 M -24.7 M - -25 M -25.6 M -30.1 M - -31.7 M -26.3 M -30.4 M - -24.1 M -18.2 M -11.3 M - -11.6 M -12.7 M -11 M - -10.9 M -10.7 M -12.1 M - -9.08 M -11.3 M -4.11 K - -16.8 K -1.82 K -4.16 K 471 - - - - - - - - - - -

Interest Expense

2.63 M - 1.51 M 192 K 1.06 M - 1.06 M 1.06 M 1.06 M - 1.07 M 1.07 M 1.04 M - 1.07 M 1.07 M 759 K - 1.97 M 1.92 M 1.87 M - 1.84 M 1.79 M 1.74 M - 1.71 M 1.38 M 1.08 M - 1.05 M 839 K 484 K - 525 K - - - - - - - - - - - - - -

EBITDA

-28.7 M - -20.1 M -27.1 M -26.2 M - -18.6 M -24.9 M -23.1 M - -23.6 M -24.1 M -28.6 M - -30.5 M -25.2 M -29.5 M - -23.2 M -17.3 M -10.6 M - -11.1 M -12.2 M -10.5 M - -10.4 M -10.3 M -11.7 M - -8.8 M -11 M 242 K - 190 K -1.82 K -4.16 K 471 - - - - - - - - - - -

Operating Expenses

28.2 M - 28.4 M 30.9 M 27.6 M - 25.2 M 24.8 M 25 M - 23.9 M 24.5 M 27.9 M - 32.3 M 29.5 M 25 M - 24.5 M 18.3 M 16.9 M - 13.6 M 12.6 M 11.1 M - 10.1 M 10.2 M 11 M - 8.31 M 10.7 M 4.11 K - 16.8 K 1.82 K 4.16 K 471 - - - - - - - - - - -

General and Administrative Expenses

11.6 M - 12.9 M 13.1 M 12.8 M - 12.5 M 13.9 M 15.6 M - 16 M 15.2 M 15.8 M - 19.4 M 15.4 M 15.1 M - 16.7 M 10.5 M 9.85 M - 7.5 M 7.46 M 7.15 M - 5.83 M 5.79 M 6.32 M - 4.28 M 1.61 K 4.32 M - 3.48 M 1.82 K 4.16 K 471 - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ViewRay VRAY
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ViewRay plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Align Technology Align Technology
ALGN
$ 153.68 1.9 % $ 11.1 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.94 1.38 % $ 121 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.79 1.98 % $ 1.62 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
AxoGen AxoGen
AXGN
$ 43.57 3.33 % $ 2.01 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 52.5 0.19 % $ 7.97 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 45.06 4.84 % $ 66.7 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.3 3.43 % $ 605 M israelIsrael
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 13.56 0.18 % $ 384 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 46.62 0.69 % $ 1.45 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 6.07 0.63 % $ 378 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 5.9 2.46 % $ 797 M usaUSA
Electromed Electromed
ELMD
$ 26.56 0.4 % $ 220 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 71.77 1.17 % $ 2.13 B costa-ricaCosta-rica
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 85.93 1.85 % $ 50.3 B usaUSA
Globus Medical Globus Medical
GMED
$ 75.39 1.62 % $ 10.2 B usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 2.28 2.7 % $ 50.3 M usaUSA
Inogen Inogen
INGN
$ 5.28 0.09 % $ 140 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.88 0.2 % $ 962 M israelIsrael
Abbott Laboratories Abbott Laboratories
ABT
$ 102.99 1.02 % $ 179 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.65 0.74 % $ 11 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 82.87 0.79 % $ 1.05 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.19 0.15 % $ 4.38 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 22.32 1.16 % $ 524 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 79.62 1.84 % $ 4.34 B britainBritain
LENSAR LENSAR
LNSR
$ 7.87 3.55 % $ 94.1 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.98 6.76 % $ 80.6 M usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 93.77 3.08 % $ 120 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.58 0.11 % $ 677 M usaUSA
Myomo Myomo
MYO
$ 1.29 1.17 % $ 54 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 0.72 2.03 % $ 46.6 M israelIsrael
InspireMD InspireMD
NSPR
$ 0.81 2.13 % $ 52.1 M israelIsrael
Orthofix Medical Orthofix Medical
OFIX
$ 9.01 0.86 % $ 357 M curacaoCuracao
Outset Medical Outset Medical
OM
$ 3.18 0.31 % $ 48.4 K usaUSA
PAVmed PAVmed
PAVM
$ 4.21 0.72 % $ 2.82 M usaUSA
Penumbra Penumbra
PEN
$ 320.04 0.73 % $ 12.5 B usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 137.17 3.95 % $ 9.65 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.86 0.17 % $ 177 M canadaCanada
Quanterix Corporation Quanterix Corporation
QTRX
$ 2.44 2.15 % $ 104 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 10.34 4.66 % $ 288 M australiaAustralia
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 1.74 2.2 % $ 4.83 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 28.44 3.42 % $ 24.7 B britainBritain
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.13 0.16 % $ 51.1 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 283.31 2.81 % $ 108 B usaUSA
TELA Bio TELA Bio
TELA
$ 1.02 5.15 % $ 47.9 M usaUSA
TransMedics Group TransMedics Group
TMDX
$ 88.05 7.14 % $ 2.99 B usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 16.97 0.06 % $ 1.15 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 8.81 0.17 % $ 343 M usaUSA